All News
Filter News
Found 2,543 articles
-
Wouldn’t it be amazing to be able to see a protein being made in a cell in real time? And wouldn’t it be even better if you could use that capability to discover new drugs to previously “undruggable” targets, creating new medicines? Well that’s exactly what Anima Biotech is aiming to do.
-
Moderna to Present at Upcoming Investor Conferences
8/27/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its participation in the following upcoming investor conferences
-
Frequency Therapeutics Expands Leadership Team
8/22/2019
Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team.
-
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
8/19/2019
Moderna, Inc., (Nasdaq: MRNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults.
-
Under the terms of the deal with Yale University, Yale researchers led by Geoff Chupp will conduct discovery research on targets associated with pulmonary diseases, then turn over the candidates to CureVac for preclinical and clinical development.
-
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
8/7/2019
Phase 2 Personalized Cancer Vaccine (mRNA-4157) study initiated, with first patient consented
-
Seres Therapeutics Appoints Stephen Berenson to its Board of Directors
8/6/2019
Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.
-
There’s clearly a need for new antibiotics to fight infections. If so, why are so many companies in the space abandoning it or going out of business?
-
In all three cancer types, data showed prolonged and consistent improvements in progression-free survival (PFS) that is similar to that seen with checkpoint inhibitor monotherapy.
-
Moderna to Present at ROTH RNA Revolution Conference
7/10/2019
Lorence Kim, M.D., Chief Financial Officer will participate in the ROTH RNA Revolution Conference on July 17, 2019.
-
This makes it one of the biggest single private funding rounds for a biotechnology company in European history.
-
ROTH Capital Partners to Host ROTH RNA Revolution Conference in New York City on July 17th, 2019
6/28/2019
ROTH Capital Partners (ROTH), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, announced today that it will host its RNA Revolution Conference on Wednesday, July 17, 2019 at the 1 Hotel Central Park in New York City.
-
Moderna to Present at BMO 2019 Prescriptions for Success Healthcare Conference
6/18/2019
Moderna, Inc. announced that Pamela Cohen, M.D., Head, Clinical Oncology Development, will present at the BMO 2019 Prescriptions for Success Healthcare Conference on Tuesday, June 25, 2019 at 3:20 p.m. ET.
-
Moderna to Present at Goldman Sachs 40th Annual Global Healthcare Conference
6/7/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Stephane Bancel, Chief Executive Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Goldman Sachs 40th Annual Global Healthcare Conference
-
Moderna Announces Presentation of Interim Data from Phase 1 Study of mRNA Personalized Cancer Vaccine at 2019 ASCO Annual Meeting
6/1/2019
Moderna, Inc. announced interim data from an ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumors.
-
BioSpace Movers and Shakers, May 31
5/31/2019
Biopharma companies from across the globe holster their leadership with new appointments. -
Growth at Flagship Pioneering Leads to New Executive Appointments
5/28/2019
Flagship Pioneering, a unique life sciences innovation enterprise, today announced the expansion of its executive partner team with new leaders dedicated to its growth-stage companies.
-
Moderna Announces Publication of Preclinical Data for Chikungunya Antibody Program
5/17/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of preclinical data in Science Immunology, showing that mRNA encoding a human monoclonal antibody against the chikungunya virus delivered in a proprietary lipid nanoparticle (LNP) can protect from infection by the virus in vivo.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
Cambridge, Mass.-based Moderna announced publication of results from two Phase I clinical trials of mRNA vaccines against two strains of influenza, H10N8 and H7N0. They were both published in the journal Vaccine.